FDA Grants Priority Review for Madrigal Pharma’s Non-Alcoholic Steatohepatitis (NASH) Treatment
Madrigal Pharmaceuticals, a leading clinical-stage biopharmaceutical company dedicated to advancing innovative treatments for nonalcoholic steatohepatitis (NASH), has exciting news to share. The U.S. ...
Madrigal Pharmaceuticals’ Resmetirom Receives FDA Breakthrough Therapy Designation for NASH Treatment with Liver Fibrosis
Madrigal Pharmaceuticals, Inc. has received U.S. Food and Drug Administration (FDA's) Breakthrough therapy designation for resmetirom in the treatment of NASH patients with liver fibrosis. The company ...